China NT Pharma Group Company Limited

1011

KYG2114L1059

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 11:36:51 2024-04-28 pm EDT			5-day change	1st Jan Change
0.027 ^HKD	+3.85%		+17.39%	-50.91%

Mar. 28	China NT Pharma Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 15	China NT Pharma Group Company Limited Announces Directorate Changes	CI

Fortune Blaze Investments Limited completed the acquisition of The Mountains Limited from China NT Pharma Group Company Limited.

June 01, 2021

Fortune Blaze Investments Limited entered into an agreement to acquire The Mountains Limited from China NT Pharma Group Company Limited (SEHK:1011) for approximately CNY 130 million on November 11, 2020. Upon Completion, The Mountains Limited and NT Pharma (China) Co., Ltd. will cease to be subsidiaries of China NT Pharma Group Company Limited and the financial results of The Mountains Limited and NT Pharma (China) Co., Ltd. will no longer be consolidated into the financial statements of the Group.

Fortune Blaze Investments Limited completed the acquisition of The Mountains Limited from China NT Pharma Group Company Limited (SEHK:1011) on June 2, 2021.

Latest news about China NT Pharma Group Company Limited

China NT Pharma Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
China NT Pharma Group Company Limited Announces Directorate Changes	Jan. 15	CI
China NT Pharma Group Company Limited Announces Change of Company Secretary, Effective 31 December 2023	Dec. 29	CI
China NT Pharma Group, Private Equity Fund Sign Cooperation Agreement; Shares Rise 4%	23-10-09	MT
China NT Pharma Raises HK$13 Million from Private Placement	23-09-22	MT
NT Pharma Seeks Nearly HK$24 Million from Share Placement	23-09-04	MT
China NT Pharma Group Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
China NT Pharma Lays Out Restructuring Plan for Embattled Unit Suzhou First Pharma	23-07-27	MT
China NT Pharma Unit Faces Lawsuits for Alleged Loan Default	23-05-02	MT
China NT Pharma Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
China Nt Pharma Group Company Limited Announces Change of Independent Non-Executive Director and Member of Audit Committee	23-01-19	CI
Konruns Pharma Cancels Osteoporosis Drug Agreement With NT Pharma, US-based Pfenex	22-12-20	MT
China NT Pharma Group Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI
China NT Pharma Group Company Limited Announces Resignation of Wu Weizhong as Executive Director and Senior Vice President	22-08-24	CI
China NT Pharma Signs Licensing Deal with US Company for Antibody Products	22-06-14	MT
China NT Pharma Group Company Limited Intends to Set Up A Joint Venture Company	22-05-17	CI
China NT Pharma Group Company Limited Updates on Delay in Publication of Audited Annual Results for the Year Ended 31 December 2021	22-04-04	CI
China NT Pharma Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
China NT Pharma : Narrows H1 Loss on Increased Antipsychotic Drug Sales	21-09-01	MT
China NT Pharma Group Company Limited Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-31	CI
China NT Pharma : NT Pharma to Narrow Loss, Increase Revenue in H1	21-08-30	MT
China NT Pharma Group Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2021	21-08-27	CI
Fortune Blaze Investments Limited completed the acquisition of The Mountains Limited from China NT Pharma Group Company Limited.	21-06-01	CI
China NT Pharma : Logs Lower Loss in 2020 as Revenue Soars 44%	21-04-06	MT
China NT Pharma Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-31	CI

Chart China NT Pharma Group Company Limited

Duration

Period

Chart China NT Pharma Group Company Limited

More charts

Company Profile

CHINA NT PHARMA GROUP COMPANY LIMITED is a China-based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company mainly conducts its businesses through two segments. The Proprietary Product Production and Sales segment is engaged in the production and sales of NT branded products and generic drugs through its subsidiaries. The Miacalcic segment is engaged in the sales and marketing of miacalcic injectable and nasal spray branded products for treatment of bone pain caused by osteolysis and lower bone mass, as well as sub-licensing of intellectual property rights and distribution rights.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CHINA NT PHARMA GROUP COMPANY LIMITED	-50.91%	8.77M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.79%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+11.98%	13.64B
ZYDUS LIFESCIENCES LIMITED	+39.05%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B